In February 2016 the J - ALEX phase III study comparing alectinib with crizotinib ALK - positive metastatic NSCLC was terminated early .
An interim analysis showed that progression - free survival was longer with alectinib .
In February 2016 the J - ALEX phase III study comparing alectinib with crizotinib ALK - positive metastatic NSCLC was terminated early because an interim analysis showed that progression - free survival was longer with alectinib .